Drug Search Results
More Filters [+]

Oxymorphone

Alternative Names: oxymorphone, opana, opana er, numorphan
Latest Update: 2024-11-27
Latest Update Note: Clinical Trial Update

Product Description

Oxymorphone is used to relieve pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated. Oxymorphone belongs to the group of medicines called narcotic analgesics (pain medicines). It acts in the central nervous system (CNS) to relieve pain. (Sourced from: https://www.mayoclinic.org/drugs-supplements/oxymorphone-oral-route/description/drg-20071555)

Mechanisms of Action: OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Canada | United States

Approved Indications: Ventricular Dysfunction | Ventricular Dysfunction, Left | Acute Pain | Pain Unspecified | Substance Abuse Unspecified | Pulmonary Edema | Dyspnea | Edema | Pain Unspecified | Substance Abuse Unspecified

Known Adverse Events: Confusion | Dizziness | Headache | Pruritus | Constipation | Abdominal Pain | Pain Unspecified | Insomnia | Diarrhea

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxymorphone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events